An Observation Placebo-controlled Trial with Cannabidiol Added-on Standard Treatment for Thai Patients Suffering from Psoriasis

• Conditions: Psoriasis patients with mild to moderate severity; Psoriasis, Cannabidiols, CBD

• Registration Number: TCTR20220208003
• Lead Sponsor: Faculty of Medicine, Western University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2022-02-08
• Study Completion: 2022-09-01
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Pending (Not yet recruiting)
• Sex: All
• Target Recruitment: 70

Inclusion Criteria

1. A patient who has been diagnosed with psoriasis, treated in the outpatient department of Nawamin Hospital, aged 18 years and over, both male and female.
2. Psoriasis patient group with mild disease severity (PASI score less than 3) or psoriasis patients with moderate disease severity (PASI score 3-10) 70 patients
3. BSA value less than 90
4. No complications from other diseases such as severe skin infections. No psoriatic arthritis conditions, cardiovascular disease.
5. Patients with normal LFT, AST (SGOT) and ALT (SGPT) not more than 2 times normal.
6. RFT eGFR value more than 59
7. Able to speak, read, listen and understand Thai language
8. Willing to cooperate/voluntarily join the trial along with signing a written consent to participate in the research project

Exclusion Criteria

1. Psoriasis patient group with a high degree of disease severity (PASI score more than 10)
2. BSA value more than 90 or increased by more than 2 times during treatment
3. LFT AST (SGOT), ALT (SGPT) greater than 2 times normal during treatment
4. RFT eGFR less than 59 (Stage 3a) during treatment.
5. Having complications from other diseases such as severe skin infections No psoriatic arthritis conditions, cardiovascular disease.
6. Patients who need to use group drugs Beta-Blockers and Oral Steroids or a history of medicinal cannabis use

Study & Design

• Study Type: Observational
• Study Design: Not specified